What was less obvious was its efficacy in delivering medicines and treatments for the most prevalent diseases in the world. Standing in the way were patents, the costs and risks of testing, and the fickle nature of medical markets.9 Nowhere was this more evident than in the scandalously slow response to the HIV/AIDS pandemic, particularly in sub-Saharan Africa. This exposed a fundamental disconnect between science, the capacities of the pharmaceutical business, and the delivery of medicines to those who needed them most.
